Journal of Neuro-Oncology

, Volume 116, Issue 1, pp 187–193

Single institution experience treating 104 vestibular schwannomas with fractionated stereotactic radiation therapy or stereotactic radiosurgery

  • Bethany M. Anderson
  • Deepak Khuntia
  • Søren M. Bentzen
  • Heather M. Geye
  • Lori L. Hayes
  • John S. Kuo
  • Mustafa K. Baskaya
  • Behnam Badie
  • Amar Basavatia
  • G. Mark Pyle
  • Wolfgang A. Tomé
  • Minesh P. Mehta
Clinical Study

DOI: 10.1007/s11060-013-1282-4

Cite this article as:
Anderson, B.M., Khuntia, D., Bentzen, S.M. et al. J Neurooncol (2014) 116: 187. doi:10.1007/s11060-013-1282-4

Abstract

The pupose of this study is to assess the long-term outcome and toxicity of fractionated stereotactic radiation therapy (FSRT) and stereotactic radiosurgery (SRS) for 100 vestibular schwannomas treated at a single institution. From 1993 to 2007, 104 patients underwent were treated with radiation therapy for vestibular schwannoma. Forty-eight patients received SRS, with a median prescription dose of 12.5 Gy for SRS (range 9.7–16 Gy). For FSRT, two different fraction schedules were employed: a conventional schedule (ConFSRT) of 1.8 Gy per fraction (Gy/F) for 25 or 28 fractions to a total dose of 45 or 50.4 Gy (n = 19); and a once weekly hypofractionated course (HypoFSRT) consisting of 4 Gy/F for 5 fractions to a total dose of 20 Gy (n = 37). Patients treated with FSRT had better baseline hearing, facial, and trigeminal nerve function, and were more likely to have a diagnosis of NF2. The 5-year progression free rate (PFR) was 97.0 after SRS, 90.5 % after HypoFSRT, and 100.0 % after ConFSRT (p = NS). Univariate analysis demonstrated that NF2 and larger tumor size (greater than the median) correlated with poorer local control, but prior surgical resection did not. Serviceable hearing was preserved in 60.0 % of SRS patients, 63.2 % of HypoFSRT patients, and 44.4 % of ConFSRT patients (p = 0.6). Similarly, there were no significant differences in 5-year rates of trigeminal toxicity facial nerve toxicity, vestibular dysfunction, or tinnitus. Conclusions:Equivalent 5-year PFR and toxicity rates are shown for patients with vestibular schwanoma selected for SRS, HypoFSRT, and ConFSRT after multidisciplinary evaluation. Factors correlating with tumor progression included NF2 and larger tumor size.

Keywords

Vestibular schwannomaAcoustic neuromaStereotactic radiosurgeryFractionated stereotactic radiation therapyRadiotherapy

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Bethany M. Anderson
    • 1
  • Deepak Khuntia
    • 5
  • Søren M. Bentzen
    • 1
  • Heather M. Geye
    • 1
  • Lori L. Hayes
    • 1
  • John S. Kuo
    • 2
  • Mustafa K. Baskaya
    • 2
  • Behnam Badie
    • 6
  • Amar Basavatia
    • 1
  • G. Mark Pyle
    • 3
  • Wolfgang A. Tomé
    • 1
    • 4
  • Minesh P. Mehta
    • 7
  1. 1.Department of Human OncologyUniversity of WisconsinMadisonUSA
  2. 2.Department of Neurological SurgeryUniversity of WisconsinMadisonUSA
  3. 3.Division of Otolaryngology, Department of SurgeryUniversity of WisconsinMadisonUSA
  4. 4.Department of Medical PhysicsUniversity of WisconsinMadisonUSA
  5. 5.Western Radiation OncologyMountain ViewUSA
  6. 6.Department of NeurosurgeryCity of Hope Cancer HospitalDuarteUSA
  7. 7.Department of Radiation OncologyUniversity of MarylandBaltimoreUSA